PhaseRx, Inc. announced unaudited earnings results for the third quarter and nine months ended September 30, 2016. For the quarter, the company reported the net loss was $3.3 million, or $0.29 per share, compared to a net loss of $1.9 million, or $3.67 per share, for the quarter ended September 30, 2015. Loss from operations was $3,138,000 compared to $1,493,000 a year ago. The net loss for the nine months ended September 30, 2016 was $16.7 million, or $2.72 per share, compared to $5.1 million, or $9.95 per share for the nine months ended September 30, 2015. Loss from operations was $15,062,000 compared to $4,127,000 a year ago.